Development of dual inhibitors targeting the viral main protease and the host cathepsin L as SARS-CoV-2 antivirals
$392,655R01FY2021AINIH
Rutgers Biomedical And Health Sciences, Newark NJ
Investigators
Linked publications, trials & patents
Paper 38076941Paper 38065031Paper 37651467Paper 37482021Paper 37329507Paper 37154751Paper 36580641Paper 36119652Paper 36060104Paper 36052369Paper 35982672Paper 35578732Paper 35474901Paper 35404564Paper 35378761Paper 35292745Paper 35284599Paper 35178512Paper 35080027Paper 34860011Paper 34745850Paper 33891389
View original record on NIH RePORTER →